Companion-Animal Gene and Cell Therapy Pipeline
As of 6 November 2026, Drugnews tracks 9 companion-animal assets: 4 approved or licensed and 5 in development, including 2 AAV gene therapies and 2 assets from Taiwan. The dataset covers 8 dog assets and 1 cat asset.
Companion-animal gene and cell therapy
The most common heart disease in older dogs is myxomatous mitral valve disease (MMVD), a leading cause of heart failure in senior dogs. In Cavalier King Charles Spaniels, incidence approaches 80%.
Today's drugs only buy time. In asymptomatic Stage B2 dogs, Boehringer Ingelheim's pimobendan extended median time to heart failure, cardiac death or euthanasia to 1,228 days versus 761 days for control, 467 days longer. The indication was conditionally approved by the FDA in 2022 and announced as fully approved in January 2026, the first time the FDA has converted a conditionally approved animal-drug indication to full approval.
To stop the valve from deteriorating, the industry is betting on gene therapy. This page tracks 9 assets: 4 approved or licensed and 5 in development, 2 of them from Taiwan's Baotai Biomedical.
01 | Pet owners already pay for a monthly injection
On 13 January 2022, the FDA approved the first monoclonal antibody for animals, for osteoarthritis pain in cats. On 5 May 2023, Zoetis's Librela (bedinvetmab) was approved for dogs as a once-monthly subcutaneous injection.
The pet biologics model works: regular vet visits for an injection, paid out of pocket. Gene and cell therapies are going after the same paying owners.
02 | Licensed gene and cell products have taken the USDA route
- Oncept: a canine melanoma DNA vaccine from Merial (now Boehringer Ingelheim), a plasmid encoding human tyrosinase, fully licensed by the USDA in 2010.
- ELIAS Cancer Immunotherapy: a patient-specific immunotherapy made from the dog's own tumor, fully licensed by the USDA in March 2025 for canine osteosarcoma.
US animal medicines have two regulators. Drugs and cell therapies go to FDA's Center for Veterinary Medicine (CVM). Biologics such as vaccines and immunotherapies go to the USDA Center for Veterinary Biologics (CVB). The route determines trial design and time to market.
03 | Five assets in development: heart, joints, mouth and cancer
Heart. Rejuvenate Bio's RJB-01 uses AAV to deliver two genes, FGF21 and soluble TGF-β receptor 2. In a 17-dog pilot, 12 Cavalier King Charles Spaniels on pimobendan went about 600 days longer to progression than historical pimobendan controls, and their left atria shrank.
Joints. CureLab Veterinary's ElenaVet is a DNA plasmid encoding p62. In a 17-dog pilot, 90% met the predefined treatment-success criteria, and the company is discussing a pivotal trial with the USDA.
Mouth. Gallant's sonruvetcel is an off-the-shelf allogeneic mesenchymal stromal cell therapy for refractory feline chronic gingivostomatitis. The FDA accepted its effectiveness section in September 2025 and its target animal safety section in November 2025; as of April 2026 conditional approval was still pending.
Cancer. Baotai's PT001 is a canine melanoma immunotherapy vaccine in field trials at veterinary hospitals across Taiwan. For the same disease, Oncept has been licensed in the US for 16 years.
Big animal-health companies have arrived. In June 2026, Merck Animal Health invested in Rejuvenate Bio and signed an R&D collaboration, and the same month formed a three-way alliance with Rejuvenate Bio and Baotai.
04 | Taiwan: where Baotai stands
Baotai Biomedical (7850) obtained exclusive Asia-Pacific rights to PT401 from Rejuvenate Bio in late 2024. PT401 is a dual-gene AAV gene therapy designed to inhibit cardiac fibrosis and regulate energy metabolism to slow MMVD.
- Thailand: the regulator approved the start of clinical testing, and Chulalongkorn University gave ethics approval in May 2026 for a Stage B1 early-intervention pilot field trial.
- Taiwan: a pivotal field trial is advancing along the existing approval pathway.
- On 9 June 2026, Baotai, Rejuvenate Bio and Merck Animal Health agreed to work together on clinical development and global commercialization.
- PT401 won Taiwan's 22nd National Innovation Award.
Early-stage work in Thailand and a pivotal trial in Taiwan spread the risk across two markets. Baotai cites an industry estimate that the global veterinary cardiology market will grow from US$2.7 billion in 2024 to US$6.1 billion in 2034.
The full Stage B2 approval for pimobendan sets the standard for early treatment: screen dogs before symptoms appear and treat early. The PT401 and RJB-01 field results will decide whether canine heart disease moves from "buying time" to "changing the course of disease".
05 | Timeline
- Ongoing: PT401 Stage B1 pilot field trial in Thailand and pivotal field trial in Taiwan.
- Under review: sonruvetcel conditional approval (still pending as of April 2026).
- Within 2–3 years: ElenaVet licensing application to the USDA, depending on funding.
Stage distribution
Species
Assets
| Asset | Company | Country | Species | Modality | Mechanism | Regulator | Stage | Indication | Deal | Latest development | Date | Sources |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Vetmedin (pimobendan), Stage B2 indication | Boehringer Ingelheim Animal Health | Germany / US | Dog | Small molecule | Inodilator | US FDA CVM | Approved (conditional converted to full) | Delaying onset of congestive heart failure in dogs with Stage B2 preclinical MMVD | — | Conditionally approved as Vetmedin-CA1 on 2022-06-16; in EPIC, median time to heart failure, cardiac death or euthanasia was 1,228 days vs 761 days (467 days longer). In January 2026 Boehringer Ingelheim announced full approval of the Stage B2 indication for Vetmedin chewable tablets and solution, the first time FDA converted a conditionally approved animal-drug indication to full approval | 2026-01-01 | 1 2 |
| ELIAS Cancer Immunotherapy | ELIAS Animal Health | US | Dog | Autologous immunotherapy | Patient-specific immunotherapy made from the dog's own tumor | USDA Center for Veterinary Biologics | Fully licensed | Canine osteosarcoma | — | Received full USDA approval in March 2025, the first autologous prescription product for canine osteosarcoma | 2025-03-18 | 1 |
| Librela (bedinvetmab) | Zoetis | US | Dog | Monoclonal antibody | Anti-nerve growth factor (NGF) | US FDA CVM | Approved | Control of osteoarthritis pain in dogs; monthly subcutaneous injection | — | FDA-approved on 2023-05-05; the first animal monoclonal antibody (for cat osteoarthritis pain) was approved on 2022-01-13 | 2023-05-05 | 1 |
| Oncept (canine melanoma DNA vaccine) | Merial (now Boehringer Ingelheim) | US | Dog | DNA plasmid vaccine | Plasmid encoding human tyrosinase that triggers an immune response against melanoma | USDA Center for Veterinary Biologics | Fully licensed | Stage II–III oral melanoma after local surgical control, to prolong survival | Developed with Memorial Sloan Kettering Cancer Center and the Animal Medical Center of New York | Received full USDA licensure in 2010 | 2010-02-16 | 1 2 |
| PT401 | Baotai Biomedical (TPEx Emerging: 7850) | Taiwan | Dog | Dual-gene AAV gene therapy | Inhibits cardiac fibrosis and regulates energy metabolism to slow progression | Thai and Taiwanese veterinary regulators | Field trials | Canine myxomatous mitral valve disease (MMVD) | Exclusive Asia-Pacific rights from Rejuvenate Bio in late 2024; on 2026-06-09, three-way alliance with Rejuvenate Bio and Merck Animal Health for clinical development and global commercialization | Thailand approved the start of clinical testing; Chulalongkorn University ethics approval in May 2026 for a Stage B1 early-intervention pilot field trial; pivotal field trial advancing in Taiwan; won Taiwan's 22nd National Innovation Award | 2026-06-09 | 1 2 3 |
| RJB-01 | Rejuvenate Bio | US | Dog | Dual-gene AAV gene therapy | Expresses FGF21 and soluble TGF-β receptor 2 (sTGFβR2) to dampen TGF-β1 | — | Pilot study | Canine MMVD | Closed a US$6M financing on 2026-06-11 with Merck Animal Health investing and signing an R&D collaboration | Pilot study in 17 dogs; in 12 Cavalier King Charles Spaniels on pimobendan, time to progression was about 600 days longer than historical pimobendan controls, and left atrial size decreased | 2026-06-11 | 1 2 |
| sonruvetcel | Gallant | US | Cat | Allogeneic mesenchymal stromal cells (off-the-shelf) | Uterine-derived mesenchymal stromal cells that modulate immunity | US FDA CVM | Under review for conditional approval | Refractory feline chronic gingivostomatitis (FCGS); also feline and canine osteoarthritis, canine atopic dermatitis, feline chronic kidney disease | US$18M Series B in June 2025 | FDA-CVM accepted the Reasonable Expectation of Effectiveness section in Sept 2025 and the Target Animal Safety section (365 days) in Nov 2025; as of April 2026 conditional approval was still pending, and a separate feline osteoarthritis product gained eligibility for the expanded conditional approval pathway | 2026-04-16 | 1 2 3 |
| ElenaVet | CureLab Veterinary | US | Dog | DNA plasmid | Encodes SQSTM1/p62 to raise the body's own anti-inflammatory mediators | USDA Center for Veterinary Biologics | Pilot study | Chronic osteoarthritis pain in dogs | — | Pilot in 17 dogs, 1 mg IM weekly for 10 weeks; 90% met predefined treatment success; pivotal protocol talks with USDA CVB, licensing application expected in 2–3 years depending on funding | 2025-06-13 | 1 |
| PT001 | Baotai Biomedical (TPEx Emerging: 7850) | Taiwan | Dog | Immunotherapy vaccine (biologic) | Therapeutic vaccine | Taiwanese veterinary regulator | Field trial enrolling | Canine melanoma | — | Enrolling in field trials at partner veterinary hospitals in northern, central and southern Taiwan; won an outstanding innovation award in 2024 | 2025-12-18 | 1 |
Frequently asked questions
Which drugs are approved for canine mitral valve disease (MMVD)?
The approved drug included in this dataset is Boehringer Ingelheim’s Vetmedin (pimobendan), to delay congestive heart failure in asymptomatic Stage B2 dogs with MMVD. This indication received FDA conditional approval in 2022, with full approval announced in January 2026.
How far has the pet gene therapy PT401 progressed?
Baotai Biomedical’s PT401 is a dual-gene AAV therapy for canine MMVD at the field-trial stage. A Stage B1 early-intervention pilot field trial has started in Thailand, while a pivotal field trial is advancing in Taiwan. On 9 June 2026, Baotai, Rejuvenate Bio and Merck Animal Health agreed to collaborate on clinical development and global commercialization.
Which agencies review new pet medicines in the United States?
Drugs and cell therapies go to the FDA Center for Veterinary Medicine (CVM). Biologics such as vaccines and immunotherapies go to the USDA Center for Veterinary Biologics (CVB). In this dataset, Vetmedin and Librela were approved by FDA CVM; Oncept and ELIAS Cancer Immunotherapy received full USDA licensure.